Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market

March 2002

Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market.

And the FDA is listening.

Many patients benefited from Lotronex to control debilitating cramping and diarrhea. The problem is that sometimes it was TOO effective...causing severe constipation and ischemic colitis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote